
WGS Stock Forecast & Price Target
WGS Analyst Ratings
Bulls say
GeneDx Holdings is positioned for robust growth, as evidenced by a significant 65% year-over-year increase in core exome/genome revenue and an impressive 33% rise in core testing volumes. The company anticipates a favorable mix-shift towards exome and genome panels, contributing to average selling prices (ASPs) of $3,850 per test, up 23% year-over-year, while also guiding for improved gross margins of 70%-71%. Additionally, GeneDx has raised its 2025 revenue guidance to $425-428 million, reflecting a strong positive outlook driven by the expansion of precision medicine and strategic targeting of pediatric neurologists in its sales approach.
Bears say
GeneDx Holdings Corp is facing a negative outlook due to expected cash burns of approximately $2 million per quarter in 2024, coupled with a high denial rate of 45% for its services, which significantly impacts its revenue generation capabilities. The company's reliance on third-party payers for reimbursement poses a substantial risk, as any amendments or renegotiations in reimbursement schedules could adversely affect its commercial success. Furthermore, challenges in maintaining supply chains for sequencers and the potential for disruptions in data and workflow services could severely hinder its operational efficacy and overall financial stability.
This aggregate rating is based on analysts' research of GeneDx Holdings Corp and is not a guaranteed prediction by Public.com or investment advice.
WGS Analyst Forecast & Price Prediction
Start investing in WGS
Order type
Buy in
Order amount
Est. shares
0 shares